CN106581023A - Western medicine for treating viral pneumonia - Google Patents
Western medicine for treating viral pneumonia Download PDFInfo
- Publication number
- CN106581023A CN106581023A CN201611171795.8A CN201611171795A CN106581023A CN 106581023 A CN106581023 A CN 106581023A CN 201611171795 A CN201611171795 A CN 201611171795A CN 106581023 A CN106581023 A CN 106581023A
- Authority
- CN
- China
- Prior art keywords
- parts
- western medicine
- glycosides
- viral pneumonia
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a western medicine for treating viral pneumonia. The western medicine for treating viral pneumonia is prepared from the following raw materials in parts by weight: 18-30 parts of aloe-emodin-8-O-heteroside, 5-15 parts of belamcandin, 8-12 parts of taraxeryl acetate, 5-12 parts of caftaric acid, 4-8 parts of karanjin, 2-6 parts of calceolarioside B, 2-8 parts of gaultherin, 7-14 parts of imperialine-e-D-glocoside and 5-18 parts of jaceosidin. The raw materials of the western medicine disclosed by the invention are strictly selected according to the knowledge mechanism for viral pneumonia, so that the purpose of comprehensive rehabilitation can be achieved; and the western medicine has the characteristics of fast effect, acting stability, portability, convenience in taking, and no toxic or side effect after long-term taking.
Description
Technical field
The present invention relates to a kind of field of medicine preparation, specifically a kind of Western medicine for treating viral pneumonia.
Background technology
Viral pneumonia is the pneumonia by upper respiratory tract infection, caused by spreading downwards.Primary disease is equal throughout the year
Can occur, but be more common in winter-spring season greatly, can break out or distribute prevalence.Clinic be mainly shown as heating, headache, systemic pain,
Dry cough and lung infiltration etc..The generation of viral pneumonia and virulence, the age of route of infection and host, the immunologic function shape of virus
State etc. is relevant.General children's sickness rate is higher than adult.
In acute respiratory infection, virus infection accounts for 90%, and virus infection has common sense then based on upper respiratory tract
Emit, pharyngitis, larynx-tracheitis and bronchitis, bronchiolitises, baby's herpangina and epidemic pleurodynia etc..Cause pneumonia
It is viral rare, wherein with influenza viruss as common, other are parainfluenza viruses, cytomegaloviruses, adenoviruss, nose
Virus, coronavirus and some enterovirus, such as COxsackie, echovirus, and herpes simplex, varicella-zoster, wind
The viruses such as rash, measles.Infant also often by respiratory syncytial virus infection produces pneumonia.Viral pneumonia is multiple to be born in winter-spring season
Section, can distribute prevalence or break out.In non-bacterial pneumonia, virus infection accounts for 25%～50%, and patient mostly is child, Cheng Renxiang
To rare.
In recent years due to immunosuppressive drug be widely used in the number of the infected of tumor, organ transplantation, and AIDS by
Year increases, and herpes simplex virus, varicella zoster viruss, cytomegaloviruses etc. can all cause serious pneumonia.Virus
Property pneumonia be apsiration infection, by the droplet infection of person to person, mainly caused by upper respiratory tract infection spreads downwards,
Often with tracheitis and bronchitis, family's pack animal, pig etc. are sometimes with certain influenza virus, accidental contagion.Excrement is oral
Infection sees enterovirus, and respiratory syncytial virus pass through dust infection.The case of organ transplantation can be by repeatedly transfusing blood, very
Organ to donor causes virus.The viral pneumonia of hematogenous spread is not with tracheitis and bronchitis.
The content of the invention
It is an object of the invention to provide a kind of Western medicine for treating viral pneumonia, to solve above-mentioned background technology in propose
Problem.
For achieving the above object, the present invention provides following technical scheme：
A kind of Western medicine for treating viral pneumonia, be according to the primary raw material of weight portion：Aloe-emodin -8-O- glucoses
Glycosides 18-30 parts, Rhizoma Belamcandae aglycon 5-15 parts, Taraxeryl acetate 8-12 parts, monocaffeyltartaric acid 5-12 parts, karanjin 4-
8 parts, calceolarioside B 2-6 parts, checkerberry glycosides 2-8 parts, BULBUS FRITILLARIAE CIRRHOSAE element glycosides 7-14 parts, Jaceosidin 5-18 parts.
As further scheme of the invention：The Western medicine of the treatment viral pneumonia, according to the primary raw material of weight portion
For：Aloe-emodin -8-O- glucoside 22-27 parts, Rhizoma Belamcandae aglycon 7-12 parts, Taraxeryl acetate 9-11 parts, single coffee
Acyl tartaric acid 7-10 parts, karanjin 4-8 parts, calceolarioside B 2-6 parts, checkerberry glycosides 2-8 parts, BULBUS FRITILLARIAE CIRRHOSAE element glycosides 7-14
Part, Jaceosidin 9-13 parts.
As further scheme of the invention：The Western medicine of the treatment viral pneumonia, according to the primary raw material of weight portion
For：25 parts of aloe-emodin -8-O- glucosides, 10 parts of Rhizoma Belamcandae aglycon, 10 parts of Taraxeryl acetate, monocaffeyltartaric acid
9 parts, 6 parts of karanjin, 4 parts of calceolarioside B, 5 parts of checkerberry glycosides, BULBUS FRITILLARIAE CIRRHOSAE element 11 parts of glycosides, 12 parts of Jaceosidin.
A kind of preparation method of the Western medicine for treating viral pneumonia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, aloe-emodin -8-O- glucosides, belamcandin are weighed by above-mentioned metering ratio
Unit, Taraxeryl acetate, monocaffeyltartaric acid, karanjin, calceolarioside B, checkerberry glycosides, BULBUS FRITILLARIAE CIRRHOSAE element glycosides, palm fibre
Cyanidin, sieves, and machinery adds ultra-pure water after mixing, and in placing pharmacy mixer, mixes 4-8min, controls RSD≤5%,
Tabletting and cold drying after mixing, at 4-8 DEG C, packaging obtains final product the Western medicine for the treatment of viral pneumonia to temperature control.
As further scheme of the invention：Mix 6min in concrete steps.
Compared with prior art, the invention has the beneficial effects as follows：
Medicine of the present invention is strictly selected material composition according to the understanding mechanism of viral pneumonia, so as to reach comprehensively
The purpose of rehabilitation, with rapid-action, effect it is stable, carry taking convenience, long-term taking and have no toxic side effect the characteristics of.
Specific embodiment
Below in conjunction with the embodiment of the present invention, the technical scheme in the embodiment of the present invention is clearly and completely described,
Obviously, described embodiment is only a part of embodiment of the invention, rather than the embodiment of whole.Based in the present invention
Embodiment, the every other embodiment that those of ordinary skill in the art are obtained under the premise of creative work is not made, all
Belong to the scope of protection of the invention.
Embodiment 1
A kind of Western medicine for treating viral pneumonia, be according to the primary raw material of weight portion：Aloe-emodin -8-O- glucoses
18 parts of glycosides, 5 parts of Rhizoma Belamcandae aglycon, 8 parts of Taraxeryl acetate, 5 parts of monocaffeyltartaric acid, 4 parts of karanjin, Caulis Akebiae phenethanol
2 parts of glycosides B, 2 parts of checkerberry glycosides, BULBUS FRITILLARIAE CIRRHOSAE 7 parts of glycosides of element, 5 parts of Jaceosidin.
A kind of preparation method of the Western medicine for treating viral pneumonia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, aloe-emodin -8-O- glucosides, belamcandin are weighed by above-mentioned metering ratio
Unit, Taraxeryl acetate, monocaffeyltartaric acid, karanjin, calceolarioside B, checkerberry glycosides, BULBUS FRITILLARIAE CIRRHOSAE element glycosides, palm fibre
Cyanidin, sieves, and machinery adds ultra-pure water after mixing, and in placing pharmacy mixer, mixes 4min, controls RSD≤5%, mixes
Tabletting and cold drying after conjunction, at 4 DEG C, packaging obtains final product the Western medicine for the treatment of viral pneumonia to temperature control.
Embodiment 2
A kind of Western medicine for treating viral pneumonia, be according to the primary raw material of weight portion：Aloe-emodin -8-O- glucoses
22 parts of glycosides, 7 parts of Rhizoma Belamcandae aglycon, 9 parts of Taraxeryl acetate, 7 parts of monocaffeyltartaric acid, 4 parts of karanjin, Caulis Akebiae phenethanol
2 parts of glycosides B, 2 parts of checkerberry glycosides, BULBUS FRITILLARIAE CIRRHOSAE 7 parts of glycosides of element, 9 parts of Jaceosidin.
A kind of preparation method of the Western medicine for treating viral pneumonia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, aloe-emodin -8-O- glucosides, belamcandin are weighed by above-mentioned metering ratio
Unit, Taraxeryl acetate, monocaffeyltartaric acid, karanjin, calceolarioside B, checkerberry glycosides, BULBUS FRITILLARIAE CIRRHOSAE element glycosides, palm fibre
Cyanidin, sieves, and machinery adds ultra-pure water after mixing, and in placing pharmacy mixer, mixes 4min, controls RSD≤5%, mixes
Tabletting and cold drying after conjunction, at 4 DEG C, packaging obtains final product the Western medicine for the treatment of viral pneumonia to temperature control.
Embodiment 3
A kind of Western medicine for treating viral pneumonia, be according to the primary raw material of weight portion：Aloe-emodin -8-O- glucoses
25 parts of glycosides, 10 parts of Rhizoma Belamcandae aglycon, 10 parts of Taraxeryl acetate, 9 parts of monocaffeyltartaric acid, 6 parts of karanjin, Caulis Akebiae benzene second
4 parts of alcohol glycosides B, 5 parts of checkerberry glycosides, BULBUS FRITILLARIAE CIRRHOSAE 11 parts of glycosides of element, 12 parts of Jaceosidin.
A kind of preparation method of the Western medicine for treating viral pneumonia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, aloe-emodin -8-O- glucosides, belamcandin are weighed by above-mentioned metering ratio
Unit, Taraxeryl acetate, monocaffeyltartaric acid, karanjin, calceolarioside B, checkerberry glycosides, BULBUS FRITILLARIAE CIRRHOSAE element glycosides, palm fibre
Cyanidin, sieves, and machinery adds ultra-pure water after mixing, and in placing pharmacy mixer, mixes 6min, controls RSD≤5%, mixes
Tabletting and cold drying after conjunction, at 6 DEG C, packaging obtains final product the Western medicine for the treatment of viral pneumonia to temperature control.
Embodiment 4
A kind of Western medicine for treating viral pneumonia, be according to the primary raw material of weight portion：Aloe-emodin -8-O- glucoses
27 parts of glycosides, 12 parts of Rhizoma Belamcandae aglycon, 11 parts of Taraxeryl acetate, 10 parts of monocaffeyltartaric acid, 8 parts of karanjin, Caulis Akebiae benzene
6 parts of ethanol glycosides B, 8 parts of checkerberry glycosides, BULBUS FRITILLARIAE CIRRHOSAE 14 parts of glycosides of element, 13 parts of Jaceosidin.
A kind of preparation method of the Western medicine for treating viral pneumonia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, aloe-emodin -8-O- glucosides, belamcandin are weighed by above-mentioned metering ratio
Unit, Taraxeryl acetate, monocaffeyltartaric acid, karanjin, calceolarioside B, checkerberry glycosides, BULBUS FRITILLARIAE CIRRHOSAE element glycosides, palm fibre
Cyanidin, sieves, and machinery adds ultra-pure water after mixing, and in placing pharmacy mixer, mixes 8min, controls RSD≤5%, mixes
Tabletting and cold drying after conjunction, at 8 DEG C, packaging obtains final product the Western medicine for the treatment of viral pneumonia to temperature control.
Embodiment 5
A kind of Western medicine for treating viral pneumonia, be according to the primary raw material of weight portion：Aloe-emodin -8-O- glucoses
30 parts of glycosides, 15 parts of Rhizoma Belamcandae aglycon, 12 parts of Taraxeryl acetate, 12 parts of monocaffeyltartaric acid, 8 parts of karanjin, Caulis Akebiae benzene
6 parts of ethanol glycosides B, 8 parts of checkerberry glycosides, BULBUS FRITILLARIAE CIRRHOSAE 14 parts of glycosides of element, 18 parts of Jaceosidin.
A kind of preparation method of the Western medicine for treating viral pneumonia, concretely comprises the following steps：
First, in pharmaceutical grade clean area, aloe-emodin -8-O- glucosides, belamcandin are weighed by above-mentioned metering ratio
Unit, Taraxeryl acetate, monocaffeyltartaric acid, karanjin, calceolarioside B, checkerberry glycosides, BULBUS FRITILLARIAE CIRRHOSAE element glycosides, palm fibre
Cyanidin, sieves, and machinery adds ultra-pure water after mixing, and in placing pharmacy mixer, mixes 8min, controls RSD≤5%, mixes
Tabletting and cold drying after conjunction, at 8 DEG C, packaging obtains final product the Western medicine for the treatment of viral pneumonia to temperature control.
Pharmacology test
1st, chronic toxicity test
With Western medicine obtained in the embodiment of the present invention 3 as test, using gastric infusion mode, successive administration 3 times in 24h,
Per minor tick 6h, 200mg/kg doses are administered every time, daily accumulation medicine total amount reaches 600mg medicines/kg, it is clinical equivalent to people to use
100 times of amount.After administration in 7d, mice activity, feed, excretion are normal, well-grown, and hair color light, its average weight is equal
Increase with the prolongation of experimental period.Every mice of post mortem at 8d, the perusal heart, liver, spleen, lung, kidney, brain, thymus,
Stomach, intestinal etc. do not find color and paramophia, fail to measure median lethal dose(LD 50) (LD50).As a result show：Western medicine of the present invention without
Chronic toxicity.
2nd, long term toxicity test
With Western medicine obtained in the embodiment of the present invention 3 as test, using gastric infusion mode, Western medicine of the present invention is divided into into low dose
Amount, middle dosage, three groups of high dose, the drug dose of each group is respectively 60,120,180mg medicines/kg/d, equivalent to clinical dosage
10,20,30 times.After gastric infusion 24 weeks, medicine of the present invention refers to the general status of animal, hematological indices, blood biochemical
Mark without significantly impact, Systematic anatomy, organ coefficient and histopathological examination also no abnormal pathological change.Drug withdrawal 2
Also substantially change is had no week.As a result show：Western medicine of the present invention does not find that overt toxicity reacts and postpones in long term toxicity test
Toxic reaction.It can be seen that, Western medicine non-toxic reaction of the present invention, long-term prescription is safe and reliable.
3rd, clinical trial
During inventor and 2 months in April, 2015 in 2016, in Shanghai, 135 patients, all patients screen in Disease Control and Prevention Center
Meet viral pneumonia disease.Wherein male 61, women 74, minimal ages 18 years old, max age 62 years old, mean age
38.5 years old.All patients take the Western medicine of the preparation of the embodiment of the present invention 3, and instructions of taking is：Daily 6mg/kg, 3 days courses for the treatment of,
Three courses for the treatment of are treated altogether.
Curative effect situation criterion：Recovery from illness：The clinical symptoms of viral pneumonia all disappear.Take a turn for the better：Viral pneumonia
Clinical symptom relief, the state of an illness is controlled.It is invalid：The clinical symptoms of viral pneumonia are without being clearly better or increase.
Therapeutic effect：135 patients, cure 97, take a turn for the better 28, invalid 10, total effective rate 92.6%.
It is obvious to a person skilled in the art that the invention is not restricted to the details of above-mentioned one exemplary embodiment, Er Qie
In the case of spirit or essential attributes without departing substantially from the present invention, the present invention can be in other specific forms realized.Therefore, no matter
From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power
Profit is required rather than described above is limited, it is intended that all in the implication and scope of the equivalency of claim by falling
Change is included in the present invention.
Moreover, it will be appreciated that although this specification is been described by according to embodiment, not each embodiment is only wrapped
Containing an independent technical scheme, this narrating mode of description is only that for clarity those skilled in the art should
Using description as an entirety, the technical scheme in each embodiment can also Jing it is appropriately combined, form those skilled in the art
Understandable other embodiment.
Claims (5)
1. a kind of Western medicine for treating viral pneumonia, it is characterised in that the primary raw material according to weight portion is：Aloe-emodin-
8-O- glucoside 18-30 parts, Rhizoma Belamcandae aglycon 5-15 parts, Taraxeryl acetate 8-12 parts, monocaffeyltartaric acid 5-12 parts,
Karanjin 4-8 parts, calceolarioside B 2-6 parts, checkerberry glycosides 2-8 parts, BULBUS FRITILLARIAE CIRRHOSAE element glycosides 7-14 parts, Jaceosidin 5-18
Part.
2. it is according to claim 1 treatment viral pneumonia Western medicine, it is characterised in that the treatment viral pneumonia
Western medicine, be according to the primary raw material of weight portion：Aloe-emodin -8-O- glucoside 22-27 parts, Rhizoma Belamcandae aglycon 7-12 parts, second
Acyl alnulin 9-11 parts, monocaffeyltartaric acid 7-10 parts, karanjin 4-8 parts, calceolarioside B 2-6 parts, winter
Green glycosides 2-8 parts, BULBUS FRITILLARIAE CIRRHOSAE element glycosides 7-14 parts, Jaceosidin 9-13 parts.
3. the Western medicine for the treatment of viral pneumonia according to claim 1 and 2, it is characterised in that the viral lung of the treatment
Scorching Western medicine, be according to the primary raw material of weight portion：25 parts of aloe-emodin -8-O- glucosides, 10 parts of Rhizoma Belamcandae aglycon, acetyl
10 parts of alnulin, 9 parts of monocaffeyltartaric acid, 6 parts of karanjin, 4 parts of calceolarioside B, 5 parts of checkerberry glycosides, western shellfish
Female 11 parts of glycosides of element, 12 parts of Jaceosidin.
4. a kind of preparation method of the Western medicine of the treatment viral pneumonia as described in claim 1-3 is arbitrary, it is characterised in that tool
Body step is：
First, in pharmaceutical grade clean area, aloe-emodin -8-O- glucosides, Rhizoma Belamcandae aglycon, second are weighed by above-mentioned metering ratio
Acyl alnulin, monocaffeyltartaric acid, karanjin, calceolarioside B, checkerberry glycosides, BULBUS FRITILLARIAE CIRRHOSAE element glycosides, brown Centaurea cyanus
Element, sieves, and machinery adds ultra-pure water after mixing, and in placing pharmacy mixer, mixes 4-8min, RSD≤5% is controlled, after mixing
Tabletting and cold drying, at 4-8 DEG C, packaging obtains final product the Western medicine for the treatment of viral pneumonia to temperature control.
5. it is according to claim 4 treatment viral pneumonia Western medicine preparation method, it is characterised in that in concrete steps
Mixing 6min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611171795.8A CN106581023A (en) | 2016-12-17 | 2016-12-17 | Western medicine for treating viral pneumonia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611171795.8A CN106581023A (en) | 2016-12-17 | 2016-12-17 | Western medicine for treating viral pneumonia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106581023A true CN106581023A (en) | 2017-04-26 |
Family
ID=58600974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611171795.8A Pending CN106581023A (en) | 2016-12-17 | 2016-12-17 | Western medicine for treating viral pneumonia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106581023A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1486699A (en) * | 2003-09-04 | 2004-04-07 | 江苏省中医药研究院 | Application of the effective part of Chinese medicinal material lindley eupatorium herb in preparing antiviral medicine |
| CN103156830A (en) * | 2011-12-13 | 2013-06-19 | 天津市国际生物医药联合研究院 | Application of aloe-emodin in resisting SARS coronavirus infection |
| CN104248654A (en) * | 2013-06-26 | 2014-12-31 | 深圳海王药业有限公司 | Application of karanjin or Pongamia pinnata extract in anti-influenza virus drugs |
-
2016
- 2016-12-17 CN CN201611171795.8A patent/CN106581023A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1486699A (en) * | 2003-09-04 | 2004-04-07 | 江苏省中医药研究院 | Application of the effective part of Chinese medicinal material lindley eupatorium herb in preparing antiviral medicine |
| CN103156830A (en) * | 2011-12-13 | 2013-06-19 | 天津市国际生物医药联合研究院 | Application of aloe-emodin in resisting SARS coronavirus infection |
| CN104248654A (en) * | 2013-06-26 | 2014-12-31 | 深圳海王药业有限公司 | Application of karanjin or Pongamia pinnata extract in anti-influenza virus drugs |
Non-Patent Citations (1)
| Title |
|---|
| 徐学民: "鸢尾苷元的结构修饰及其体外抗SARS病毒的活性研究", 《万方数据 第三届中医药现代化国际科技大会论文集》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI792162B (en) | A compound traditional Chinese medicine with the function of clearing lung and expelling toxin and its application | |
| CN102085311B (en) | Traditional Chinese medicinal composition for preventing or treating common cold and/or flu, method for preparing same and application thereof | |
| CN103394070B (en) | Treat grippal Chinese medicine preparation | |
| CN102319294B (en) | Double-vanilla preparation and preparation method thereof | |
| CN102784282A (en) | Medicine for clearing heat, removing toxicity and reducing fever | |
| CN102139051B (en) | Application of soft capsule capable of clearing heat and eliminating toxin in preparation of medicament for treating viral pneumonia | |
| CN105079635A (en) | Moisturizing ointment for relieving infantile eczema | |
| CN106727907A (en) | A kind of Chinese and Western medicine combination for treating viral pneumonia and preparation method thereof | |
| CN106581023A (en) | Western medicine for treating viral pneumonia | |
| CN102240345A (en) | Compound Chinese herbal medicine preparation for preventing and treating Newcastle disease | |
| CN113332377B (en) | Chinese medicinal compound preparation for treating viral pneumonia | |
| CN103386081B (en) | Traditional Chinese medicine preparation for curing respiratory tract infection in clinical nursing | |
| CN106692457A (en) | Medicine for treating viral pneumonia | |
| CN106581274A (en) | Chinese and western medicine composite for treating amygdalitis and preparing method thereof | |
| CN106581031A (en) | Compound Western medicine for treating pertussis | |
| CN106511440A (en) | Compound Chinese and Western medicine composition for treating chronic dysentery and preparation method thereof | |
| CN103230568B (en) | Benorilate vitamin B1 particle for children and preparation process thereof | |
| CN106668600A (en) | Composite preparation for treating chronic glomerulitis | |
| CN106727642A (en) | A kind of children's antipyretic | |
| CN104888123A (en) | Preparation for infantile respiratory tract infection as well as preparation method and detection method thereof | |
| CN103099851A (en) | Pharmaceutical composition for treating cold and preparation method thereof | |
| CN102475810A (en) | Viral influenza treating medicine | |
| CN105664080A (en) | Medicine for treating influenza | |
| CN102755554B (en) | Chinese medicine for preventing and treating measles | |
| CN103784706A (en) | Medicine composition for treating intestinal tympany of equus animals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170426 |